Publisher Correction: Cytoplasmic FBXO38 mediates PD-1 degradation

被引：0

作者：

Xiwei Liu ^{[1
]}

Xiangbo Meng ^{[2
]}

Zuomiao Lin ^{[3
]}

Shutan Jiang ^{[1
]}

Haifeng Liu ^{[1
]}

Shao-cong Sun ^{[4
]}

Xiaolong Liu ^{[1
]}

Penghui Zhou ^{[5
]}

Xiaowu Huang ^{[6
]}

Lai Wei ^{[7
]}

Wei Yang ^{[8
]}

Chenqi Xu ^{[9
]}

机构：

[1] Chinese Academy of Sciences,CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology

[2] Shandong University,Advanced Medical Research Institute, Meili Lake Translational Research Park, Cheeloo College of Medicine

[3] University of Chinese Academy of Sciences,School of Life Science, Hangzhou Institute for Advanced Study

[4] Chinese Institutes for Medical Research,Institute of Immunology

[5] Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine

[6] Fudan University,Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital

[7] Ministry of Education,Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University)

[8] Fudan University,Shanghai Key Laboratory of Organ Transplantation, Zhongshan Hospital

[9] Guangzhou Medical University,Guangdong Provincial Key Laboratory of Allergy & Clinical Immunology, The Second Affiliated Hospital

[10] Southern Medical University,Guangdong Provincial Key Laboratory of Molecular Oncologic Pathology, Department of Pathology, School of Basic Medical Sciences

[11] Southern Medical University,Department of Pathology, Nanfang Hospital

来源：

EMBO Reports | 2024年 / 25卷 / 12期

关键词：

D O I：

10.1038/s44319-024-00298-0

中图分类号：

学科分类号：

摘要：

[graphic not available: see fulltext]

引用

页码：5838 / 5838

共 50 条

[21] Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
Leonie Voorwerk
Maarten Slagter
Hugo M. Horlings
Karolina Sikorska
Koen K. van de Vijver
Michiel de Maaker
Iris Nederlof
Roelof J. C. Kluin
Sarah Warren
SuFey Ong
Terry G. Wiersma
Nicola S. Russell
Ferry Lalezari
Philip C. Schouten
Noor A. M. Bakker
Steven L. C. Ketelaars
Dennis Peters
Charlotte A. H. Lange
Erik van Werkhoven
Harm van Tinteren
Ingrid A. M. Mandjes
Inge Kemper
Suzanne Onderwater
Myriam Chalabi
Sofie Wilgenhof
John B. A. G. Haanen
Roberto Salgado
Karin E. de Visser
Gabe S. Sonke
Lodewyk F. A. Wessels
Sabine C. Linn
Ton N. Schumacher
Christian U. Blank
Marleen Kok
Nature Medicine, 2019, 25 : 1175 - 1175
[22] Correction to: Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors
Sadal Refae
Jocelyn Gal
Nathalie Ebran
Josiane Otto
Delphine Borchiellini
Frederic Peyrade
Emmanuel Chamorey
Patrick Brest
Gérard Milano
Esma Saada-Bouzid
Investigational New Drugs, 2021, 39 : 287 - 292
[23] PD-1 mediates decidual γδT cells cytotoxicity during recurrent pregnancy loss
Guo, Rong
Jiang, Silin
Zhang, Jianliang
Yang, Quanli
Gao, Liang
Xia, Wei
Tong, Lingxia
Feng, Peiran
Xu, Yan
Zhang, Tao
Cheng, Hao
Liu, CuiPing
Zhang, Xueguang
Yin, Zhinan
Zhang, Hong
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2022, 88 (03)
[24] PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma
Beldi-Ferchiou, Asma
Lambert, Marion
Dogniaux, Stephanie
Vely, Frederic
Vivier, Eric
Olive, Daniel
Dupuy, Stephanie
Levasseur, Frank
Zucman, David
Lebbe, Celeste
Sene, Damien
Hivroz, Claire
Caillat-Zucman, Sophie
ONCOTARGET, 2016, 7 (45) : 72961 - 72977
[25] PD-1 mediates brain resident memory T cell formation and virus control
Butic, Arrienne
Lauver, Matthew
Lukacher, Aron
JOURNAL OF IMMUNOLOGY, 2024, 212 (01):
[26] CD38-Mediated Immunometabolic Suppression as a Mechanism of Resistance to PD-1/PD-L1 Axis Blockade
Chen, L.
Diao, L.
Yang, Y.
Yi, X.
Rodriguez, B. L.
Li, Y.
Rodriguez-Canales, J.
Liu, X.
Huang, A.
Zhao, Q.
Peng, D.
Fradette, J.
Tong, P.
Ungewiss, C.
Fan, Y.
Peng, D.
Villalobos, P.
Dmitrovsky, E.
Papadimitrakopoulou, V.
Wang, J.
Byers, L. A.
Heymach, J.
Ullrich, S.
Wistuba, I.
Qin, X.
Gibbons, D.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1779 - S1779
[27] Alternative splicing of PBRM1 mediates resistance to PD-1 blockade therapy in renal cancer
Cho, Namjoon
Kim, Seung-Yeon
Lee, Sung-Gwon
Park, Chungoo
Choi, Sunkyung
Kim, Eun-Mi
Kim, Kee K.
EMBO JOURNAL, 2024, : 5421 - 5444
[28] Correction: Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer
Mei Gao
Miranda Lin
Richard A. Moffitt
Marcela A. Salazar
Jinha Park
Jeffrey Vacirca
Chuan Huang
Kenneth R. Shroyer
Minsig Choi
Georgios V. Georgakis
Aaron R. Sasson
Mark A. Talamini
Joseph Kim
British Journal of Cancer, 2020, 123 : 495 - 495
[29] PD-1 interaction with PD-L1 but not PD-L2 on B cells mediates protective effects of estrogen against EAE
Bodhankar, Sheetal
Offner, Halina
JOURNAL OF IMMUNOLOGY, 2013, 190
[30] 0.1% Nano-silver mediates PD-1/PD-L1 pathway and alleviates chronic apical periodontitis in rats
Xinxin Sun
Boqi Li
Dilinuer Abula
Liping Wang
Bangyao Wang
Qi Wang
Tao Liu
Ruihan Zhang
Li Sheng
Yinghao Jing
Bei Zhang
Yishan Liu
Odontology, 2023, 111 : 154 - 164

← 1 2 3 4 5 →